{"id":527,"date":"2021-09-22T16:36:08","date_gmt":"2021-09-22T19:36:08","guid":{"rendered":"https:\/\/pequenoprincipe.org.br\/newsano5\/en\/?p=527"},"modified":"2022-03-16T14:48:52","modified_gmt":"2022-03-16T17:48:52","slug":"research-seeks-to-develop-a-new-treatment-for-parkinsons-disease","status":"publish","type":"post","link":"https:\/\/pequenoprincipe.org.br\/newsano5\/en\/8\/research-seeks-to-develop-a-new-treatment-for-parkinsons-disease\/","title":{"rendered":"Research seeks to develop a new treatment for Parkinson\u2019s disease"},"content":{"rendered":"\n
\"\"<\/figure><\/div>\n\n\n\n

Parkinson\u2019s disease is a progressive and degenerative neurological movement disorder that affects thousands of people around the world. As it progresses, the disease becomes increasingly disabling, making it difficult or impossible to perform simple daily activities, such as bathing or dressing. Many of the symptoms of Parkinson\u2019s disease involve motor control, the ability to control your muscles and movements. These changes are mainly because of the death of dopaminergic neurons.<\/p>\n\n\n\n

The worldwide cost of drugs for this disease is estimated to be around US$ 11 billion, with treatment being about three to four times more expensive for patients in advanced stages of the disease. Existing treatments are symptomatic, that is, they partially replace the missing dopamine, but do not prevent the disease from progressing. The research project led by scientist and neurologist Katherine Athayde Teixeira de Carvalho and her team, from the Pel\u00e9 Pequeno Pr\u00edncipe Research Institute, seeks the development of a new treatment, capable of preventing the death of neurons, thus preserving the quality of life of sufferers and reducing treatment costs.<\/p>\n\n\n\n

\u201cStem cells have regenerative capacity and differentiation potential. Evidence suggests that the therapeutic effect of these cells comes from extracellular products, such as microRNAs. In light of this, our study proposes a therapy based on microRNAs. The microRNAs that do not exhibit toxic effects are incorporated into nanoemulsions and used in preclinical testing. Parkinson\u2019s disease is induced in mice, and the animals are treated for four to eight weeks with the nanomedication. Thus, the development of a safe nanomedication is expected for a future clinical trial proposition,\u201d explains the researcher. The new therapy will be tested via nasal and intravenous routes.<\/p>\n\n\n\n

\"\"<\/figure><\/div>\n\n\n\n

\u201cWe will have three years to develop the project, at the end of which we hope to contribute to the offer of a more resolutive, more economical treatment with results in more quality of life for patients with Parkinson\u2019s disease served by the Public Health System (SUS),\u201d emphasizes the scientist.<\/p>\n\n\n\n

Funding<\/strong>
The research was approved in the National Program of Genomics and Precision Health, launched by the federal government in 2020 to encourage scientific and technological development in the areas of genomics and precision health within the SUS, besides boosting the growth of the national genomics industry. For its development, it received an investment of more than US$ 566,000.<\/p>\n\n\n\n

Cellular Processing Center<\/strong>
The research group led by Dr. Katherine is also working on a new project, which intends to implement a Cellular Processing Center at the Research Institute for the supply of stem cells and their derivatives in the scope of innovative cell therapy throughout the country.<\/p>\n\n\n\n

\u201cThis is a dream we have, but it will depend on a lot of support from society for implementation, because of its high costs,\u201d highlights the Institute\u2019s director-general, Ety Cristina Forte Carneiro.<\/p>\n\n\n\n

With the implantation of the Cellular Processing Center it will be possible to isolate and cultivate stem cells from various tissues, such as adipose and hematopoietic; supply stem cells for allogeneic and autologous therapies for the standard and already established treatment for some diseases; develop investigative therapies for untreated diseases, also called orphan diseases; and generate revenues that maintain the Center itself, besides contributing to the economic sustainability of the Pequeno Pr\u00edncipe Complex.<\/p>\n","protected":false},"excerpt":{"rendered":"

The project proposes the development of a nanomedication that prevents the advance of the illness, improving the quality of life of patients<\/p>\n","protected":false},"author":2,"featured_media":543,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[8],"tags":[],"acf":[],"_links":{"self":[{"href":"https:\/\/pequenoprincipe.org.br\/newsano5\/en\/wp-json\/wp\/v2\/posts\/527"}],"collection":[{"href":"https:\/\/pequenoprincipe.org.br\/newsano5\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pequenoprincipe.org.br\/newsano5\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pequenoprincipe.org.br\/newsano5\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/pequenoprincipe.org.br\/newsano5\/en\/wp-json\/wp\/v2\/comments?post=527"}],"version-history":[{"count":9,"href":"https:\/\/pequenoprincipe.org.br\/newsano5\/en\/wp-json\/wp\/v2\/posts\/527\/revisions"}],"predecessor-version":[{"id":748,"href":"https:\/\/pequenoprincipe.org.br\/newsano5\/en\/wp-json\/wp\/v2\/posts\/527\/revisions\/748"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pequenoprincipe.org.br\/newsano5\/en\/wp-json\/wp\/v2\/media\/543"}],"wp:attachment":[{"href":"https:\/\/pequenoprincipe.org.br\/newsano5\/en\/wp-json\/wp\/v2\/media?parent=527"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pequenoprincipe.org.br\/newsano5\/en\/wp-json\/wp\/v2\/categories?post=527"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pequenoprincipe.org.br\/newsano5\/en\/wp-json\/wp\/v2\/tags?post=527"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}